Isdn (Isosorbide Dinitrate)

After oral administration, isosorbide dinitrate is converted to nitric oxide in the bloodstream. Nitric oxide activates guanylate cyclase, raising cyclic GMP levels in vascular smooth muscle, which causes relaxation of arteries and veins, reduces preload and afterload, and lowers myocardial oxygen demand.

The dose of Isdn is individualized and set by the prescribing clinician based on the patient’s clinical condition, response to therapy, and tolerance. Dosage adjustments may be required for elderly patients, those with renal or hepatic impairment, or when used with other vasodilators.

Isdn is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy if the potential benefit justifies the risk. Limited data are available for breastfeeding, so a risk‑benefit assessment should be performed.

To order Isdn, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Isdn belongs to the organic nitrate class, similar to nitroglycerin, but it has a longer half‑life and is often used for chronic management rather than acute relief. Compared with beta‑blockers, it primarily reduces preload and afterload rather than heart rate, making it useful in patients who cannot tolerate beta‑blockade.

Store Isdn at ambient temperature below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Isdn is taken orally, usually as a whole tablet swallowed with a glass of water. It may be taken with or without food, but patients should follow the prescriber’s instructions regarding timing, especially if a nitrate‑free interval is required to reduce tolerance.

The most serious adverse events include severe hypotension, syncope, myocardial infarction or worsening ischemia, life‑threatening arrhythmias, and allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, chest pain, or signs of an allergic response.

Isdn is contraindicated in patients with severe anemia, known hypersensitivity to organic nitrates, uncontrolled hypotension, recent use of phosphodiesterase‑5 inhibitors, or those who have experienced a recent severe myocardial infarction without medical supervision. Clinicians should review the full contraindication list before prescribing.